



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	222465	METAGENICS RESVERATROL HEALTHY AGEING COMPLEX
ARTG entry for	Medicine Listed	
Sponsor	Metagenics (Aust) Pty Ltd	
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
ARTG Start Date	14/04/2014	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS RESVERATROL HEALTHY AGEING COMPLEX

Product Type	Single Medicine Product	Effective Date	29/01/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body in elderly individuals
- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support general health and wellbeing in aging individuals
- Traditionally used in Chinese medicine to maintain/support healthy blood circulation
- Helps maintain/support healthy blood sugar/glucose in healthy individuals
- Maintain/support cardiovascular system health in healthy individuals
- Maintain/support healthy cardiovascular system function in elderly individuals
- Maintain/support healthy cardiovascular system function in healthy individuals
- Traditionally used in Chinese medicine to maintain/support healthy immune system function
- Maintain/support healthy immune system function in healthy individuals

Indication Requirements

- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to serious immunological diseases.
- Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Standard Indications

No Standard Indications included on Record

Specific Indications



Australian Government
Department of Health
Therapeutic Goods Administration

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Curcuma longa root Extract dry concentrate	152 mg
Equivalent: Curcuma longa (Dry)	3.8 g
quercetin	200 mg
Reynoutria japonica root Extract dry concentrate standardised	600 mg
Equivalent: Reynoutria japonica (Dry)	60 g

Other Ingredients (Excipients)

Carnauba Wax
chlorophyllin-copper complex
colloidal anhydrous silica
croscarmellose sodium
hypromellose
macrogol 8000
magnesium stearate
microcrystalline cellulose
sodium starch glycollate type A

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary